Minimal inhibitory concentrations of first-line drugs of multidrug -resistant tuberculosis isolates

Lung India

Volumn 29, Issue 4, 2012, Pages 309-312

  Schönfeld, Nicolas ^a   Bergmann, Thorsten ^a   Vesenbeckh, Silvan ^a   Mauch, Harald ^a   Bettermann, Gudrun ^a   Bauer, Torsten T ^a   Rüssmann, Holger ^a  

^a HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

Ethambutol; isoniazid; low level resistance; minimal inhibitory concentrations; multidrug resistance; tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

EID: 84870261338     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.102794     Document Type: Article

References (16)

1. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-9.
2. Springer B, Calligaris-Maibach RC, Ritter C, Böttger EC. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: Semiquantitative drug susceptibility testing and genotyping. J Clin Infect Microbiol 2008;46:4064-7.
3. Schaaf HS, Victor TC, Engelke E, Brittle W, Marais BJ, Hesseling AC, et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Microbiol Infect Dis 2006;26:203-5.
4. NCCLS. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes, vol. 23: Approved standard M24-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003.
5. DIN Deutsches Institut für Normung e. V. Medical microbiology -Diagnosis of tuberculosis. Part 8: Methods for the determination of susceptibility of tubercle bacilli to chemotherapeutic agents. Berlin, Germany: Beuth Verlag; 2009.
6. Kent PT, Kubica GP. Public health mycobacteriology. A guide for the level III laboratory. Atlanta, GA: Center for Disease Control and Prevention; 1985.
7. Geerligs WA, Van Altena R, De Lange WCM, Van Soolingen D, van Der Werf TS. Multidrug-resistant tuberculosis: Long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000;4:758-64.
8. Schaberg T, Reichert B, Schülin T, Lode H, Mauch H. Rapid drug susceptibility testing of Mycobacterium tuberculosis using conventional solid media. Eur Respir J 1995;8:1688-93.
9. Kim SJ. Drug-susceptibility testing in tuberculosis: Methods and reliability of results. Eur Respir J 2005;25:564-9.
10. Nuernberger E, Grosset J. Pharmacokinetic and pharmacodynamics issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-55.
11. Böttger E. Drug-resistant tuberculosis. Lancet 2001;357:1288-9.
12. Espinal MA, Kim SI, Suarez G, Kam KM, Kohmenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcomes in 6 countries. JAMA 2000;283:2537-45.
13. Richter E, Mauch H, Beer R, Diel R, Hillemann D, Hofmann H, et al. MIQ 5: Tuberkulose/Mykobakteriose. In: Podbielski A, Herrmann M, Kniehl E, Mauch H, Rüssmann H, editors. Qualitätsstandards in der mikrobiologisch- infektiologischen Diagnostik. 2nd ed. München: Elsevier GmbH Urban and Fischer; 2010. p. 1-75.
14. Gagneux S, Burgis MV, DeRiemer K, Encisco A, Muños S, Hopewell PC, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PloS Pathog 2006;2:e61.
15. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999;3:703-10.
16. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008. Geneva: World Health Organization; 2008.